VEGFA and ovarian carcinoma: Some targeted agents, such as the anti-vascular endothelial growth factor (VEGF) antibodies and poly (ADP-ribose) polymerase inhibitors PARPi, improve the outcomes in patients with ovarian cancer [4,5].